Johnson & Johnson on Wednesday posted a 32% rise in fourth-quarter profit, boosted by demand for its cancer drugs Darzalex and Imbruvica.
The company's net earnings rose to $4.01 billion, or $1.50 per share, in the quarter, from $3.04 billion, or $1.12 per share, a year earlier.
Total sales rose to 1.7% to $20.75 billion.
(Reporting by Manas Mishra and Saumya Sibi Joseph in Bengaluru Editing by Saumyadeb Chakrabarty) ((saumya.joseph@thomsonreuters.com; within U.S. +1 646 223 8780, outside U.S. +91 80 6749 2290; Twitter: @SaumyaSibi;))
